To directly assess the effect of Bro40 peptide on treating EGFR TKI-resistant NSCLC, we generated cell penetrating Bro40 peptide by fusing Bro40, along with 8 Arginine residues (R8), to the C-terminus of His-MBP. This evidence concerns the gene MBP and non-small cell lung carcinoma.